NEXI NexImmune Inc: Enterprise Value-to-Revenue Multiple

Public company logo of neximmune.com (NEXI)

Due to the neutral geopolitical status of medicine, NexImmune, Inc. (NEXI) continues to steadily advance its research. The EV/Sales trend on the GURU.Markets chart confirms the success of the standardized T-cell training method for cost reduction and the implementation of IT modeling for various tumors. Meanwhile, records a new level, verifying the current business valuation relative to revenue, excluding debt load.

Company Value to Revenue: NexImmune Inc (NEXI) for 07/04/2022 - 11/20/2026

neximmune.com - analytical breakdowns and key metrics (NEXI)

- share price and consensus valuation forecast:
Initial company analysis:NexImmune, Inc. NEXI
Product sample of NexImmune, Inc.

NexImmune, Inc. (NEXI) innovative developments in T-cell programming and its patent protection create high business value even under strict FDA oversight. The ratio of enterprise value to revenue, reflected in the EV/Sales multiple, allows for an assessment of the market premium for R&D potential accounting for the debt load, where a downward trend on the chart signals rising operational risks.

Competitor analysis for NexImmune, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gritstone Bio (GRTS)|KA (Kineta Corp) - EV/Sales Multiple|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP